0001209191-17-052684.txt : 20170913
0001209191-17-052684.hdr.sgml : 20170913
20170913173835
ACCESSION NUMBER: 0001209191-17-052684
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170911
FILED AS OF DATE: 20170913
DATE AS OF CHANGE: 20170913
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nielsen Ulrik B.
CENTRAL INDEX KEY: 0001531962
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35409
FILM NUMBER: 171083888
MAIL ADDRESS:
STREET 1: MERRIMACK PHARMACEUTICALS, INC.
STREET 2: ONE KENDALL SQUARE, SUITE B7201
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MERRIMACK PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001274792
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE KENDALL SQUARE
STREET 2: SUITE B7201
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-441-1000
MAIL ADDRESS:
STREET 1: ONE KENDALL SQUARE
STREET 2: SUITE B7201
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-09-11
0
0001274792
MERRIMACK PHARMACEUTICALS INC
MACK
0001531962
Nielsen Ulrik B.
C/O MERRIMACK PHARMACEUTICALS, INC.
ONE KENDALL SQUARE, SUITE B7201
CAMBRIDGE
MA
02139
1
0
0
0
Common Stock
2017-09-11
4
M
0
14756
13.20
A
37437
D
Common Stock
2017-09-11
4
S
0
14756
14.46
D
22681
D
Common Stock
2017-09-13
4
M
0
6800
13.20
A
29481
D
Common Stock
2017-09-13
4
S
0
6800
14.27
D
22681
D
Stock Option (right to buy)
13.20
2017-09-11
4
M
0
14756
0.00
D
2017-10-04
Common Stock
14756
14033
D
Stock Option (right to buy)
13.20
2017-09-13
4
M
0
6800
0.00
D
2017-10-04
Common Stock
6800
7233
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.43 to $14.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.15 to $14.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
The one-for-ten reverse stock split of the Issuer's common stock that became effective for trading purposes on September 6, 2017 resulted in the reporting person's ownership of 204,130 fewer shares of common stock.
This option was previously reported as covering 146,622 shares of common stock at an exercise price of $2.59 per share, but was adjusted to reflect both the special cash dividend that was payable on May 26, 2017 and the reverse stock split that became effective for trading purposes on September 6, 2017.
This option is fully vested.
/s/ Brian J. Kickham, attorney-in-fact
2017-09-13